Search Clinical Trials
Terminated
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal (External Link)
Everolimus has significantly improved outcomes following prior therapy. This study is a biomarker driven Phase II trial that will assess the activity of everolimus as first-line therapy for renal cell …
Terminated
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (External Link)
To generate CMV-T cells we put a specially produced carrier virus (adenovirus) that carries one CMV gene into the patient's blood monocytes or dendritic cells. These cells are then used …
Baylor Role:
Lead Sponsor
Terminated
Genetic Susceptibility to Kidney Cancer (External Link)
This study will further the understanding of the genetic events leading to the development of RCC; explore the genetic basis for genetic instability and how it affects cancer risk; and …
Baylor Role:
Lead Sponsor
Terminated
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE (External Link)
To participate in this transplant, the patient will need to have a central line. Before the transplant we will test the blood for viruses which can cause problems after the …
Baylor Role:
Lead Sponsor
Terminated
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE (External Link)
Before the transplant we will test the patients blood for viruses which can cause problems after the transplant. These viruses include Hepatitis B, (which causes liver damage), cytomegalovirus, (which causes …
Baylor Role:
Lead Sponsor
Terminated
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) (External Link)
Allogeneic stem cell transplantation with high-dose chemotherapy affords a better chance of cure of malignant and non-malignant hematological diseases compared to autologous transplantation, because of the lack of stem cell …
Baylor Role:
Lead Sponsor
Terminated
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma (External Link)
Infusions of CD45 MAbs A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used 40, 400ug/kg …
Baylor Role:
Lead Sponsor
Terminated
LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL) (External Link)
Investigators first tested a biopsy of the tumor that has already been done to see if the tumor cells are EBV positive. They then got permission to take up to …
Baylor Role:
Lead Sponsor
Terminated
Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine (External Link)
WHAT IS INVOLVED IN THE STUDY? Before participating in this study, there will be a screening process. Administration: Gemcitabine will be received directly into the cerebrospinal fluid (fluid that circulates …
Baylor Role:
Lead Sponsor
Terminated
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (External Link)
We expect that the patient's participation in this study will last approximately 18 months to 2 years. Before treatment begins, they will be evaluated to confirm they meet the requirements …
Baylor Role:
Lead Sponsor